Latest Breaking News On - Anheart therapeutics inc - Page 1 : comparemela.com
Share:
HANGZHOU, China and NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) AnHeart Therapeutics Co., Ltd. ( AnHeart ), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually on June 4-8, 2021. Details on the abstract and a corresponding poster presentation are shown below.
Abstract Number: 9066
Abstract Title:
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
ChinaBeijingNew-yorkUnited-statesTongjiSichuanShanghaiHangzhouZhejiangAmericanIrina-kofflerAkira-jing-liu